Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Enhanced HIV type 1 neutralization by human anti-glycoprotein 120 monoclonal antibodies in the presence of monoclonal antibodies to lymphocyte function-associated molecule 1.

AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):523-31. Unique Identifier : AIDSLINE MED/99236718
Hioe CE; Hildreth JE; Zolla-Pazner S; Department of Pathology, New York University Medical Center and; Manhattan VA Medical Center, New York 10010, USA.

Abstract: Cellular adhesion receptor LFA-1 and its ICAM ligands are known to play a role in HIV infection. The presence of these molecules on virions and target cells promotes virus infectivity and has previously been shown to hinder virus neutralization by anti-HIV antibodies. To delineate the effect of these molecules on neutralization of HIV-1, human monoclonal antibodies (MAbs) to V3 and the CD4-binding domain (CD4bd) of gp120 were examined in the presence of anti-LFA-1 MAbs. When either of two anti-LFA-1 MAbs was present, higher levels of virus neutralization were achieved by both anti-V3 and anti-CD4bd MAbs. This effect was observed with primary HIV-1 isolates as well as with a laboratory-adapted strain. However, this activity was seen only when an anti-LFA-1 MAb was combined with anti-gp120 MAbs that exhibited virus-specific neutralizing activities, demonstrating the specificity of both the anti-LFA-1 and anti-gp120 MAbs. Enhanced neutralization by anti-gp120 MAbs was observed if the anti-LFA-1 MAb was present during the initial 24 hr only, if added 24 hr after infection, or if present throughout the culture period. These data suggest that the anti-LFA-1 MAbs could act at different stages of HIV-1 infection, including the initial virus-cell interaction as well as during the amplification and spread of virus from cell to cell. These findings demonstrate the significant role of LFA-1 in HIV-1 infection and have important implications for evaluating the neutralizing activity of anti-HIV antibodies.

Keywords: JOURNAL ARTICLE Antibodies, Monoclonal/*IMMUNOLOGY Antibody Specificity Dose-Response Relationship, Immunologic Human HIV Antibodies/*IMMUNOLOGY HIV Envelope Protein gp120/*IMMUNOLOGY HIV-1/*IMMUNOLOGY Lymphocyte Function-Associated Antigen-1/*IMMUNOLOGY Neutralization Tests Support, U.S. Gov't, Non-P.H.S. Support, U.S. Gov't, P.H.S.
990930
A9991332

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .